The abstract submission system will open in early February 2023
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
Regular abstracts |
10 May 2023, 21:00hrs CEST |
Late-breaking abstracts |
14 September 2023, 21:00hrs CEST |
Outcome notifications
Outcome notifications are expected to be made available to first authors and submitters between 19 and 21 July 2023.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end September.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website in early August 2023, in the section “Information for Presenters”.
Abstract submission categories
Basic science |
NSCLC, early stage |
Biliary tract cancer, incl. cholangiocarcinoma |
NSCLC, locally advanced |
Biomarkers (agnostic) |
NSCLC, metastatic |
Breast cancer, early stage |
Oesophagogastric cancer |
Breast cancer, locally advanced |
Palliative care |
Breast cancer, metastatic |
Pancreatic cancer |
CNS tumours |
Policy and preventive strategies |
Colorectal cancer |
Prostate cancer |
Developmental therapeutics |
Psycho-oncology |
Endocrine tumours |
Renal cancer |
Germ cell (testicular) cancer and penile cancer |
Sarcoma |
Gynaecological cancers |
SCLC |
Haematological malignancies |
Supportive care |
Head and neck cancer, excluding thyroid |
Thoracic malignancies, other |
Hepatocellular carcinoma (HCC) |
Thyroid cancer |
Investigational immunotherapy |
Translational research (agnostic) |
Melanoma and other skin tumours |
Tumour biology and pathology |
Miscellaneous |
Urothelial cancer |
Neuroendocrine tumours |
*Cancer nursing |
New diagnostic tools |
*Abstract categories for submissions to the European Oncology Nursing Society (EONS) for the Cancer nursing track are to be announced. Submissions in these categories will be reviewed by the EONS Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherwise stated, submissions in the Cancer nursing categories must follow all regular ESMO 2023 submission regulations and guidelines.
Late-breaking abstracts (LBA)
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO Congress 2023.
A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on 10 May 2023.
Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 14 September 2023, 21:00 CEST (Central European Summer Time).
The final late-breaking abstract deadline of 14 September 2023 is under no circumstances to be considered as an extension of the general submission deadline.
Trial in progress abstracts (TiP)
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Congress 2023.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections: Background and Trial design.
- Recruitment must have already begun or have been completed by the abstract submission deadline of 10 May 2023
- Abstracts including results or preliminary data will be rejected
- Trial in Progress abstracts can be accepted for Poster presentation only
- Encore TiP abstracts will not be accepted
Publication schedule of accepted abstracts
Details regarding the publication of accepted abstracts will be available on this page in due course.
Presentation of accepted abstracts
The ESMO Congress 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
The complete Abstract regulation document will be available on this page in early February 2023.